Vyne Therapeutics Stock Alpha and Beta Analysis
| VYNE Stock | USD 3.03 0.13 4.48% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vyne Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vyne Therapeutics over a specified time horizon. Remember, high Vyne Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vyne Therapeutics' market risk premium analysis include:
Beta (0.34) | Alpha 0.78 | Risk 4.41 | Sharpe Ratio 0.2 | Expected Return 0.87 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Vyne |
Vyne Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vyne Therapeutics market risk premium is the additional return an investor will receive from holding Vyne Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vyne Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vyne Therapeutics' performance over market.| α | 0.78 | β | -0.34 |
Vyne Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vyne Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Vyne Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vyne Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Vyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vyne Therapeutics shares will generate the highest return on investment. By understating and applying Vyne Therapeutics stock market price indicators, traders can identify Vyne Therapeutics position entry and exit signals to maximize returns.
Vyne Therapeutics Return and Market Media
The median price of Vyne Therapeutics for the period between Sun, Aug 25, 2024 and Sat, Nov 23, 2024 is 1.91 with a coefficient of variation of 21.3. The daily time series for the period is distributed with a sample standard deviation of 0.47, arithmetic mean of 2.23, and mean deviation of 0.42. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Tarabut Acquires UK Payments Platform Vyne Ahead of New MENA Regulatory Requirements | 09/03/2024 |
2 | VYNE Therapeutics Inc. Reports Q2 Loss, Tops Revenue Estimates - MSN | 09/24/2024 |
3 | Disposition of 105 shares by Harsch Mutya of Vyne Therapeutics at 1.88 subject to Rule 16b-3 | 09/30/2024 |
4 | Were Keeping An Eye On VYNE Therapeutics Cash Burn Rate | 10/09/2024 |
5 | Disposition of 1154 shares by Harsch Mutya of Vyne Therapeutics at 3.83 subject to Rule 16b-3 | 10/18/2024 |
6 | Acquisition by David Domzalski of 4429 shares of Vyne Therapeutics at 2.159 subject to Rule 16b-3 | 11/01/2024 |
7 | BioCryst Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates | 11/04/2024 |
8 | VYNE Therapeutics GAAP EPS of -0.29, revenue of 0.1M | 11/07/2024 |
9 | VYNE Therapeutics Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN | 11/20/2024 |
About Vyne Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vyne or other stocks. Alpha measures the amount that position in Vyne Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2020 | 2021 | 2023 | 2024 (projected) | Payables Turnover | 0.29 | 0.51 | 0.46 | 0.24 | Days Of Inventory On Hand | 1.9K | 794.87 | 914.1 | 1.5K |
Vyne Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Vyne Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vyne Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vyne Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vyne Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vyne Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vyne Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Vyne Therapeutics Backtesting, Vyne Therapeutics Valuation, Vyne Therapeutics Correlation, Vyne Therapeutics Hype Analysis, Vyne Therapeutics Volatility, Vyne Therapeutics History and analyze Vyne Therapeutics Performance. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Vyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.